NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals announced that its board has approved a stock buyback plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to analysts' expectations of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $1.38 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

18 analysts have issued 12-month price objectives for Alexion Pharmaceuticals' stock. Their forecasts range from $130.00 to $180.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $161.1765 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View Analyst Ratings for Alexion Pharmaceuticals.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Alexion Pharmaceuticals include Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY) and ASTELLAS PHARMA/ADR (ALPMY).

News stories about ALXN stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Alexion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Swedbank (0.37%), Bank of Montreal Can (0.30%), Factory Mutual Insurance Co. (0.27%), Assenagon Asset Management S.A. (0.14%), Boston Advisors LLC (0.11%) and Peregrine Capital Management LLC (0.07%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Stralem & Co. Inc., Channing Capital Management LLC, Hartford Investment Management Co., Covenant Asset Management LLC, Creative Planning, Handelsbanken Fonder AB, Gateway Investment Advisers LLC and Sit Investment Associates Inc.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was bought by a variety of institutional investors in the last quarter, including Swedbank, Assenagon Asset Management S.A., Factory Mutual Insurance Co., Bank of Montreal Can, Vigilant Capital Management LLC, Boston Advisors LLC, Oakbrook Investments LLC and Mitsubishi UFJ Asset Management UK Ltd.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $135.16.

Alexion Pharmaceuticals has a market capitalization of $30.07 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]